Article and Video CATEGORIES
The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi and welcome to Grace. Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...
Hi Amber, Welcome to Grace. I'm so sorry you're going through this scare. It could be a recurrence. It also is as likely to be the contrast creating a better view. ...
Hi Blaze,
As much as I hate to say it, Welcome back Blaze. It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...
Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3
It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...
Hello and welcome to Grace. I'm sorry you're worrying about this but it probably isn't cancer.
From Adenocarcinoma of the lung: from BAC to the future, "GGNs with diameter...